R. Tamura, Difference in Immunosuppressive Cells Between Peritumoral Area and 627 Tumor Core in Glioblastoma, World Neurosurg, vol.120, pp.601-610, 2018.

Q. Wang, Vascular niche IL-6 induces alternative macrophage activation in glioblastoma 629 through HIF-2?, Nat. Commun, vol.9, p.559, 2018.

K. Turkowski, VEGF as a modulator of the innate immune response in glioblastoma

, Glia, vol.66, pp.161-174, 2018.

X. Cui, Hacking macrophage-associated immunosuppression for regulating glioblastoma 633 angiogenesis, Biomaterials, vol.161, pp.164-178, 2018.

C. Zhu, CECR1-mediated cross talk between macrophages and vascular mural cells 635 promotes neovascularization in malignant glioma, Oncogene, vol.36, pp.5356-5368, 2017.

L. Deng, SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be 637 Monitored by MRI, Neoplasia (United States), vol.19, pp.1-7, 2017.

J. P. Gagner, Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes 639 with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination

, J. Pathol, vol.187, pp.2080-2094, 2017.

D. Hanahan, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-74, 2011.

J. Mieczkowski, Down-regulation of IKK? expression in glioma-infiltrating 643 microglia/macrophages is associated with defective inflammatory/immune gene responses in 644 glioblastoma, Oncotarget, vol.6, pp.33077-33090, 2015.

B. R. Achyut, Canonical NF?B signaling in myeloid cells is required for the 646 glioblastoma growth, Sci. Rep, vol.7, pp.1-12, 2017.

R. Kumar, Modulating glioma-mediated myeloid-derived suppressor cell development 648 with sulforaphane, PLoS One, vol.12, pp.1-26, 2017.

T. Barberi, Absence of host NF-?B p50 induces murine glioblastoma tumor regression, 650 increases survival, and decreases T-cell induction of tumor-associated macrophage M2 651 polarization, Cancer Immunol. Immunother, vol.67, pp.1491-1503, 2018.

G. Kohanbash, GM-CSF promotes the immunosuppressive activity of glioma-infiltrating 653 myeloid cells through interleukin-4 receptor-?, Cancer Res, vol.73, pp.6413-6423, 2013.

M. Zhou, Serum macrophage-derived chemokine/CCL22 levels are associated with 655 glioma risk, CD4 T cell lymphopenia and survival time, Int. J. Cancer, vol.137, pp.826-836, 2015.

K. Latha, The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant 657 Progression in Glioma, JNCI J. Natl. Cancer Inst, vol.111, pp.1-9, 2018.

D. C. Strachan, CSF1R inhibition delays cervical and mammary tumor growth in murine 659 models by attenuating the turnover of tumor-associated macrophages and enhancing 660 infiltration by CD8+T cells, Oncoimmunology, vol.2, pp.1-12, 2013.

H. Sadahiro, Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune 662 Microenvironment in Glioblastoma, Cancer Res, vol.78, p.3013, 2018.

W. A. Flavahan, Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor 664 Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune 665 Evasion, Stem Cells, vol.34, pp.2026-2039, 2016.

F. Herisson, Metabolic and 669 functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in 670 glioblastoma, Nat. Neurosci, 2018.

R. G. Carroll, An unexpected link between fatty acid synthase and cholesterol synthesis 672 in proinflammatory macrophage activation, J. Biol. Chem, p.673, 2018.

S. H. Baik, A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction 675 in Alzheimer's Disease, Cell Metab, 2019.

X. Hu, Microglia/macrophage polarization dynamics reveal novel mechanism of injury 677 expansion after focal cerebral ischemia, Stroke, vol.43, pp.3063-3070, 2012.

T. Hide, Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma 679 Stem Cell Niches at the Tumor Border. EBioMedicine, vol.30, pp.94-104, 2018.

S. Deborde, Schwann cells induce cancer cell dispersion and invasion Find the latest 681 version : Schwann cells induce cancer cell dispersion and invasion, vol.126, pp.1538-1554, 2016.

J. A. Stratton, Macrophages Regulate Schwann Cell Maturation after Nerve Injury, Cell 683 Rep, vol.24, pp.2561-2572, 2018.

B. Kong, C. W. Michalski, H. Friess, and J. Kleeff, Surgical procedure as an inducer of tumor 685 angiogenesis, Exp. Oncol, vol.32, pp.186-189, 2010.

H. Zhu, Surgical debulking promotes recruitment of macrophages and triggers 687 glioblastoma phagocytosis in combination with CD47 blocking immunotherapy, Oncotarget, vol.8, pp.12145-12157, 2017.

N. A. Hung, Telomere profiles and tumor-associated macrophages with different 690 immune signatures affect prognosis in glioblastoma, Mod. Pathol, vol.29, pp.212-226, 2016.

K. Gupta and T. C. Burns, Radiation-Induced Alterations in the Recurrent Glioblastoma 692 Microenvironment: Therapeutic Implications. Front, Oncol, vol.8, p.503, 2018.

P. Tabatabaei, Radiotherapy induces an immediate inflammatory reaction in malignant 694 glioma: a clinical microdialysis study, J. Neurooncol, vol.131, pp.83-92, 2017.

K. P. Bhat, Mesenchymal Differentiation Mediated by NF-?B Promotes Radiation 696 Resistance in Glioblastoma, Cancer Cell, vol.24, pp.331-346, 2013.

M. M. Leblond, M2 macrophages are more resistant than M1 macrophages following 698 radiation therapy in the context of glioblastoma, Oncotarget, vol.8, pp.72597-72612, 2017.

M. Okubo, M2-polarized macrophages contribute to neovasculogenesis, leading to 700 relapse of oral cancer following radiation, Sci. Rep, vol.6, pp.1-12, 2016.

N. B. Doan, Identification of radiation responsive genes and transcriptome profiling via 702 complete RNA sequencing in a stable radioresistant U87 glioblastoma model, Oncotarget, vol.9, pp.23532-23542, 2018.

S. C. Wang, C. F. Yu, J. H. Hong, C. S. Tsai, and C. S. Chiang, Radiation Therapy-Induced, p.705

, Tumor Invasiveness Is Associated with SDF-1-Regulated Macrophage Mobilization and 706 Vasculogenesis, PLoS One, vol.8, 2013.

G. J. Kitange, Expression of CD74 in high grade gliomas: a potential role in 708 temozolomide resistance, J. Neurooncol, vol.100, pp.177-186, 2010.

A. L. Hudson, Glioblastoma Recurrence Correlates With Increased APE1 and 710 Polarization Toward an Immuno-Suppressive Microenvironment, Front. Oncol, vol.8, 2018.

M. Kazantseva, Elevation of the TP53 isoform ?133p53? in glioblastomas: an 712 alternative to mutant p53 in promoting tumor development, J. Pathol, vol.246, pp.77-88, 2018.

N. Arsic, The p53 isoform ?133p53? promotes cancer stem cell potential, Stem cell, vol.714, issue.4, pp.531-540, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01703033

A. L. Chang, CCL2 Produced by the Glioma Microenvironment Is Essential for the 716 Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells, Cancer Res, vol.76, pp.5671-5682, 2016.

K. J. Pienta, Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody 719 against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

, Invest. New Drugs, vol.31, pp.760-768, 2013.

I. Brana, Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in tumors: 723 an open-label, multicenter phase 1b study, Target. Oncol, vol.10, pp.111-123, 2015.

S. K. Sandhu, A first-in-human, first-in-class, phase i study of carlumab (CNTO 888), a 725 human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

, Cancer Chemother. Pharmacol, vol.71, pp.1041-1050, 2013.

T. M. Nywening, Targeting tumour-associated macrophages with CCR2 inhibition in 728 combination with FOLFIRINOX in patients with borderline resectable and locally advanced 729 pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised

, Lancet. Oncol, vol.17, pp.651-662, 2016.

S. K. Biswas and A. Mantovani, Macrophage plasticity and interaction with lymphocyte 732 subsets: Cancer as a paradigm, Nat. Immunol, vol.11, pp.889-896, 2010.

T. A. Wynn, A. Chawla, and J. W. Pollard, Origins and Hallmarks of Macrophages: 734 Development, Homeostasis, and Disease, Nature, vol.496, pp.445-55, 2013.

H. Zhao, CD47 promotes tumor invasion and metastasis in non-small cell lung cancer

, Sci. Rep, vol.6, p.1, 2016.

H. Zhang, HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of 738 phagocytosis and maintenance of cancer stem cells, Proc. Natl. Acad. Sci, vol.112, pp.6215-6223, 2015.

G. Hutter, Microglia are effector cells of CD47-SIRP? antiphagocytic axis disruption 741 against glioblastoma, Proc. Natl. Acad. Sci. U. S. A, vol.116, pp.997-1006, 2019.

M. Zhang, Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and 743 M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo, PLoS One, vol.11, pp.153550-0153550, 2016.

F. Li, Blocking the CD47-SIRP? axis by delivery of anti-CD47 antibody induces 746 antitumor effects in glioma and glioma stem cells, Oncoimmunology, vol.7, pp.1391973-1391973, 2017.

S. Gholamin, Disrupting the CD47-SIRP? anti-phagocytic axis by a humanized anti-749 CD47 antibody is an efficacious treatment for malignant pediatric brain tumors, Sci. Transl

. Med, , vol.9, pp.1-14, 2017.

B. I. Sikic, A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and 752 pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in 753 patients with advanced solid tumors, J. Clin. Oncol, vol.36, p.3002, 2018.

J. Guillon, Regulation of senescence escape by TSP1 and CD47 following chemotherapy 755 treatment, Cell Death Dis, 2019.

T. Shoji, Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal 757 antibody induces antitumor effects in mouse glioma models, Neuro. Oncol, vol.18, pp.1120-1128, 2016.

R. H. Vonderheide, Phase i study of the CD40 agonist antibody CP-870,893 combined 760 with carboplatin and paclitaxel in patients with advanced solid tumors, Oncoimmunology, vol.2, p.10, 2013.

A. K. Nowak, A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in 763 combination with cisplatin and pemetrexed in malignant pleural mesothelioma, Ann. Oncol, vol.764, pp.2483-2490, 2015.

S. Hoves, Rapid activation of tumor-associated macrophages boosts preexisting tumor 766 immunity, J. Exp. Med. jem, vol.20171440, 2018.

C. J. Perry, Myeloid-targeted immunotherapies act in synergy to induce inflammation 768 and antitumor immunity, J. Exp. Med, vol.215, pp.877-893, 2018.

Y. Feng, A toll-like receptor agonist mimicking microbial signal to generate tumorprovisional file, not the final typeset article suppressive macrophages, Nat Commun, vol.10, p.2272, 2019.

S. Adams, Rejection of Skin Metastases in Patients With Breast Cancer, Clin. cancer, vol.772, issue.18, pp.6748-6757, 2013.

A. Z. Dudek, First in human phase I trial of 852A, a novel systemic toll-like receptor 7 774 agonist, to activate innate immune responses in patients with advanced cancer, Clin. Cancer 775 Res, vol.13, pp.7119-7125, 2007.

D. A. Smith, Antitumor activity and safety of combination therapy with the Toll-like 777 receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small 778 cell lung cancer patients who have progressed following chemotherapy, Cancer Immunol

. Immunother, , vol.63, pp.787-796, 2014.

A. Ranjan, Exosomes as a biomarker platform for detecting epidermal growth factor 781 receptor-positive high-grade gliomas, J. Neurosurg, p.782, 2017.

G. Zhang, CD133 positive U87 glioblastoma cells-derived exosomal microRNAs in 784 hypoxia-versus normoxia-microenviroment, J. Neurooncol, vol.135, pp.37-46, 2017.

K. Gabrusiewicz, Glioblastoma stem cell-derived exosomes induce M2 macrophages and 786 PD-L1 expression on human monocytes, Oncoimmunology, vol.7, 2018.

K. E. Van-der-vos, Directly visualized glioblastoma-derived extracellular vesicles 788 transfer RNA to microglia/macrophages in the brain, Neuro. Oncol, vol.18, pp.58-69, 2016.

J. De-vrij, Glioblastoma-derived extracellular vesicles modify the phenotype of 790 monocytic cells, Int. J. Cancer, vol.137, pp.1630-1642, 2015.

L. A. Harshyne, B. J. Nasca, L. C. Kenyon, D. W. Andrews, and D. C. Hooper, Serum 792 exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of 793 glioblastoma patients, Neuro. Oncol, vol.18, pp.206-215, 2016.

S. J. Coniglio and J. E. Segall, Review: Molecular mechanism of microglia stimulated 795 glioblastoma invasion, Matrix Biol, vol.32, pp.372-380, 2013.

D. Yan, Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-797 mediated therapeutic resistance in gliomas, Oncogene, vol.36, pp.6049-6058, 2017.

W. D. Tap, Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell 799 Tumor, N. Engl. J. Med, vol.373, pp.428-437, 2015.

N. Butowski, Orally administered colony stimulating factor 1 receptor inhibitor 801 PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials 802 Consortium phase II study, Neuro. Oncol, vol.18, pp.557-564, 2016.

H. H. Van-acker, S. Anguille, Y. Willemen, E. L. Smits, and V. F. Van-tendeloo, 804 Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials

, Pharmacol. Ther, vol.158, pp.24-40, 2016.

R. E. Kast, Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and 807 immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin

, Tumor Biol, vol.39, p.1010428317699797, 2017.

B. C. Kennedy, Tumor-associated macrophages in glioma: friend or foe?, J. Oncol, vol.810, p.486912, 2013.

C. C. Poon, S. Sarkar, V. W. Yong, and J. J. Kelly, Glioblastoma-associated microglia and 812 macrophages: Targets for therapies to improve prognosis, Brain, vol.140, pp.1548-1560, 2017.

Z. Chen and D. Hambardzumyan, Immune Microenvironment in Glioblastoma Subtypes

, Immunol, vol.9, p.1004, 2018.

D. Hambardzumyan, D. H. Gutmann, and H. Kettenmann, The role of microglia and 816 macrophages in glioma maintenance and progression, Nat. Neurosci, vol.19, p.20, 2015.

W. Zhou, Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated 818 macrophages and promotes malignant growth, Nat. Cell Biol, vol.17, pp.170-182, 2015.

J. Lee, Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic 820 inflammation, Neuro. Oncol, vol.17, pp.685-696, 2015.

M. E. Hardee, Resistance of glioblastoma-initiating cells to radiation mediated by the 822 tumor microenvironment can be abolished by inhibiting transforming growth factor-?, Cancer 823 Res, vol.72, pp.4119-4129, 2012.

, A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand, vol.2, p.825

, in Participants With Metastatic Castrate-Resistant Prostate Cancer. 826 150. A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of 827 Care) Chemotherapy in Patients With Solid Tumors

, First Study of the Safety of CNTO 888 in Patients With Solid Tumors

, Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic 830 Pancreatic Patients (CCR2i)

, Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or 833 Without CCX872-B. 834 155. BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable 198, Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With 915 Borderline Resectable Adenocarcinoma of the Pancreas, vol.832

, Safety Study of PLX108-01 in Patients With Solid Tumors. 920 202. A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced 921 Melanoma and Other Solid Tumors. 922 203. A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma. 923 204. Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant, A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants 917 With Advanced Solid Tumors. 918 200. LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma. 919 201

, Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer. 926 206. A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

+. Nivolumab and . Cabiralizumab, Gemcitabine Versus Gemcitabine in Patients With Stage IV 928 Pancreatic Cancer Achieving Disease Control in Response to First-line, Chemotherapy, vol.929

, Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced 931 Cancers, pp.8-11

, A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in 933 Patients With Solid Tumors. 934 210. CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute 935 Myeloid Leukemia

, A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

, Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in 938 Advanced Solid Tumors. 939 213. A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants 940 With Advanced Solid Tumors

, Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women 943 With Stage I or Stage II Breast Cancer. 944 216. Bonefos and the Consumption of Analgesics (BICAM)

, Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic 946 Prostate Cancer. 947 218. S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

A. H. Paterson, Oral clodronate for adjuvant treatment of operable breast cancer 949 (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-950 controlled, randomised trial, Lancet. Oncol, vol.13, pp.734-742, 2012.

, Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma. 952 221. N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or 953 Refractory High-Risk Neuroblastoma

, Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With